Reported 7 days ago
H.C. Wainwright analyst Robert Burns has upheld a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) while reducing the price target from $53 to $46, despite the company's decision to halt the Phase 3 portion of the STELLAR-305 trial. This trial was pivotal for validating the performance of their zanzalintinib drug. The new target reflects a nearly 21% upside from the current market price of $38.12, although analysts suggest that other AI stocks may present better investment opportunities.
Source: YAHOO